Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M.

J Clin Oncol. 2011 Jun 10;29(17):2372-7. doi: 10.1200/JCO.2010.33.0688. Epub 2011 May 9.

PMID:
21555696
2.

Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Scarpa A, Mantovani W, Capelli P, Beghelli S, Boninsegna L, Bettini R, Panzuto F, Pederzoli P, delle Fave G, Falconi M.

Mod Pathol. 2010 Jun;23(6):824-33. doi: 10.1038/modpathol.2010.58. Epub 2010 Mar 19.

3.

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas.

Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC.

J Clin Oncol. 2004 Dec 1;22(23):4762-71. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570077
4.
5.

DNA copy number status is a powerful predictor of poor survival in endocrine pancreatic tumor patients.

Jonkers YM, Claessen SM, Perren A, Schmitt AM, Hofland LJ, de Herder W, de Krijger RR, Verhofstad AA, Hermus AR, Kummer JA, Skogseid B, Volante M, Voogd AC, Ramaekers FC, Speel EJ.

Endocr Relat Cancer. 2007 Sep;14(3):769-79.

6.

Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas.

Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, Scarpa A, Pederzoli P, Falconi M.

Dig Liver Dis. 2009 Jan;41(1):49-55. doi: 10.1016/j.dld.2008.03.015. Epub 2008 May 7.

PMID:
18463008
7.

Prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.

Papadoniou N, Kosmas C, Gennatas K, Polyzos A, Mouratidou D, Skopelitis E, Tzivras M, Sougioultzis S, Papastratis G, Karatzas G, Papalambros E, Tsavaris N.

Anticancer Res. 2008 Jan-Feb;28(1B):543-9.

8.

En bloc resection for locally advanced cancer of the pancreas: is it worthwhile?

Sasson AR, Hoffman JP, Ross EA, Kagan SA, Pingpank JF, Eisenberg BL.

J Gastrointest Surg. 2002 Mar-Apr;6(2):147-57; discussion 157-8.

PMID:
11992799
9.

Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas.

Müller MW, Friess H, Köninger J, Martin D, Wente MN, Hinz U, Ceyhan GO, Blaha P, Kleeff J, Büchler MW.

Am J Surg. 2008 Feb;195(2):221-8.

PMID:
18154768
10.

Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy.

Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T.

Pancreas. 1996 Apr;12(3):267-71.

PMID:
8830333
11.

Stereotactic body radiation therapy boost in locally advanced pancreatic cancer.

Seo Y, Kim MS, Yoo S, Cho C, Yang K, Yoo H, Choi C, Lee D, Kim J, Kim MS, Kang H, Kim Y.

Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1456-61. doi: 10.1016/j.ijrobp.2009.01.042. Epub 2009 Sep 23.

PMID:
19783379
12.

Positive peritoneal lavage cytology is a predictor of worse survival in locally advanced pancreatic cancer.

Clark CJ, Traverso LW.

Am J Surg. 2010 May;199(5):657-62. doi: 10.1016/j.amjsurg.2010.01.021.

PMID:
20466112
13.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
14.

Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.

Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, Fisher GA, Ford JM, Desser T, Quon A, Koong AC.

Cancer. 2009 Feb 1;115(3):665-72. doi: 10.1002/cncr.24059.

15.

Telomerase activity in pancreatic endocrine tumors.

Tang SJ, Dumot JA, Wang L, Memmesheimer C, Conwell DL, Zuccaro G, Goormastic M, Ormsby AH, Cowell J.

Am J Gastroenterol. 2002 Apr;97(4):1022-30.

PMID:
12003383
16.

A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma.

Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr, Benson AB 3rd.

Am J Clin Oncol. 2007 Feb;30(1):26-31.

PMID:
17278891
17.

Prognostic criteria in nonfunctioning pancreatic endocrine tumours.

La Rosa S, Sessa F, Capella C, Riva C, Leone BE, Klersy C, Rindi G, Solcia E.

Virchows Arch. 1996 Dec;429(6):323-33.

PMID:
8982376
18.

Microwave ablation in locally advanced pancreatic carcinoma--a new look.

Lygidakis NJ, Sharma SK, Papastratis P, Zivanovic V, Kefalourous H, Koshariya M, Lintzeris I, Porfiris T, Koutsiouroumba D.

Hepatogastroenterology. 2007 Jul-Aug;54(77):1305-10.

PMID:
17708242
19.

Pancreatic head carcinoma: clinical analysis of 189 cases.

Hua YP, Liang LJ, Peng BG, Li SQ, Huang JF.

Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):79-84.

PMID:
19208521
20.

Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.

Panzuto F, Nasoni S, Falconi M, Corleto VD, Capurso G, Cassetta S, Di Fonzo M, Tornatore V, Milione M, Angeletti S, Cattaruzza MS, Ziparo V, Bordi C, Pederzoli P, Delle Fave G.

Endocr Relat Cancer. 2005 Dec;12(4):1083-92.

Supplemental Content

Support Center